Exiqon

Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.

The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.

The company said its offer received acceptances from nearly 95 percent of Exiqon shareholders, and it expects to close the deal by June 28.

Qiagen has again extended the offer period and has reduced the acceptance threshold for share capital and voting rights.

Qiagen will hold a greater than 90 percent stake in Exiqon if members of Exiqon's management convert warrants they hold to shares rather than to cash.

In March, Qiagen announced that it had made a roughly $100 million offer for Exiqon in an effort to expand its presence in the RNA analysis field.

Product revenues were up slightly due to the firm's entry into new markets, while services revenues tumbled due to market fluctuations.

Qiagen has submitted an offer to buy all of Exiqon's shares for DKK18 each, for a total aggregate purchase price of DKK683 million ($103.5 million).

The firm's product revenues grew 29 percent year over year to DKK 24.7 million, and it is launching a new online sales platform next month.

Pages

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.